Natalia Rost, MD / Boston Potamkin Prize for Analysis in Pick’s, Alzheimer’s, and Related Diseases Sponsored by the American Academy of Neurology, the American Academy of Neurology Basis and funded through the philanthropy of the Potamkin Family members. Takeshi Iwatsubo, MD, PhD / Tokyo Neuroendocrine Analysis Award Sponsored by the American Academy of Neurology and backed by friends of Andrew Herzog, MD. Alison Pack, MD / New York Analysis Award in Geriatric Neurology Sponsored by the American Academy of Neurology and the Academy’s Geriatric Neurology Section. Gil Rabinovici, MD / SAN FRANCISCO BAY AREA Bruce S.Moore also reiterated reported results from a placebo-controlled research which evaluated the safety previously, tolerability, and efficacy of ALB-127158. The study, comprising the one ascending dosage and 14-time multiple ascending dose arms, included regular safety assessments, ECG monitoring, and PK measurements. ALB-127158 was well tolerated in both the SAD and the MAD. Reported events were mild and showed little dosage relationship. One of the most common events reported in both the SAD and the MAD was loss of urge for food.